

2024 Taipei International Breast Cancer Symposium

Right Choice for Right Patient

Room 701A, Taipei Nangang Exhibition Center, Hall 2

Sat., October 26, 2024

Time	Topic	Speaker	Moderator
08:30-09:00	Opening	Shou-Tung Chen	
Special Lecture			
09:00-09:30	Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs	Kenji Tamura	King-Jen Chang
Diversity of Triple Negative Breast Cancer and the Role of Immunotherapy			
09:30-10:00	Are All Triple Negative Breast Cancers the Same?	Jorge S. Reis-Filho	Cheng-Ping Yu
10:00-10:30	Current status and future prospects of immunotherapy in Breast cancer treatment, past, now and future	Tan Jing Ying Tira	Ching-Hung Lin
10:30-10:50	Coffee Break		
10:50-11:20	Precision immunotherapy for TNBC, from clinical factors to tumor microenvironment	Giampaolo Bianchini	Hsien-Kun Chang
11:20-11:50	From Consistent 1L CDK4/6i Evidence Based Survival Benefit to Real World Clinical Practice in HR+HER2 mBC	Shih-Yu Huang	Kuo-Ting Lee
11:50-12:10	Panel Discussion	Jorge S. Reis-Filho Tan Jing Ying Tira Giampaolo Bianchini Shih-Yu Huang	Ming-Feng Hou Takashi Ishikawa
12:10-12:50	Luncheon Symposium (1) Docetaxel, Aging Like a Fine Wine	Chun-Yu Liu	Liang-Chih Liu
12:50-13:10	Coffee Break		
Advance in the Management of Luminal Disease			
13:10-13:40	The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/Her2- Node+ High Risk Early Breast Cancer	Nadia Harbeck	Dar-Ren Chen
13:40-14:10	Adjuvant Treatment for Young Age ER+ Early Breast Cancer (EBC)	Prudence Francis	Shyr-Ming Sheen-Chen
14:10-14:40	Bridging Treatment Gaps for Stage II and III HR+/HER2- Early Breast Cancer with CDK4/6 Inhibitors	Stephen Chia	Fang-Ming Chen
14:40-15:00	Coffee Break		
15:00-15:30	Long-Term Survival Benefits of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer: Insights from Real-World Evidence	Hope S. Rugo	Fiona Tsui-Fen Cheng
15:30-16:00	Novel Strategies to Overcome Resistance to Endocrine Therapy in HR+ aBC: From Biological Perspectives to Clinical Advances	Javier Cortés	Tsu-Yi Chao
16:00-16:20	Panel Discussion	Prudence Francis Stephen Chia Hope S. Rugo Javier Cortés	Shin-Cheh Chen Shinji Ohno
Antibody-Drug-Conjugate: Innovations and Future Directions			
16:20-16:50	Navigating ADC to Clinical Success With the Learning from Current Research	Leif Ellisen	Chiun-Sheng Huang
16:50-17:20	Riding the Wave of Innovation: The evolving landscape of ADCs in Breast Cancer Treatment	Paolo Tarantino	Jiun-I Lai
17:20-17:50	Optimizing Survival: Individualized Adjuvant Strategies for Maximizing Neoadjuvant Benefits	Sibylle Loibl	Ling-Ming Tseng
17:50-18:10	Panel Discussion	Leif Ellisen Paolo Tarantino Sibylle Loibl	Yen-Shen Lu

2024 Taipei International Breast Cancer Symposium

Right Choice for Right Patient

Room 701A, Taipei Nangang Exhibition Center, Hall 2

Sun., October 27, 2024

Time	Topic	Speaker	Moderator
Breakfast Symposium			
08:20-08:50	The Current Role of Combination Chemotherapy in Metastatic Breast Cancer Treatment	Ta-Chung Chao	Nei-Min Chu
Locoregional Treatment			
08:50-09:20	Axillary Surgery in Clinically Node Negative and Positive Disease: Current Indication	Jai Min Ryu	Yao-Jen Chang
09:20-10:00	Current Topics in Breast Cancer Radiation Oncology: Axillary Management, Multi-Centric Disease, and Second Breast-Conserving Therapy	Philip Poortmans	Jyh-Cherng Yu
10:00-10:30	How to Avoid Axillary Dissection in Breast Cancer Patients with Metastatic Axillary Lymph Nodes on Preoperative Ultrasound?	Jana de Boniface	Chao-Ming Hung
10:30-10:50	Panel Discussion	Jai Min Ryu Philip Poortmans Jana de Boniface	Guo-Shiou Liao Wonshik Han
10:50-11:10	Coffee Break		
Manipulating Estrogen Receptor Positive Cancer Cell: From Molecular Insights to Clinical Practices			
11:10-11:40	Breast Cancer Biology for Precision Medicine	Christos Sotiriou	Wen-Hung Kuo
11:40-12:10	Diagnostic and Therapeutic Considerations in Tumor Microenvironments	Mark Pegram	Chi-Cheng Huang
Concerning Not Only About Cancer			
12:10-12:50	Luncheon Symposium (2) Real World Evidence: Astragalus Polysaccharides Injection and Breast Cancer Patients with Cancer-Related Fatigue	Ming-Shen Dai	Kun-Ming Rau
12:50-13:10	Coffee Break		
13:10-13:40	Unmet Needs in Early Stage HER2 Positive Breast Cancer: the Benefit of Extended Adjuvant treatment	Hsu-Huan Chou	Shih-Che Shen
13:40-14:10	Cardio-Oncology: Protecting the Heart as Curative Breast Cancer Treatment	Wei-Ting Chang	Hsien-Tang Yeh
14:10-14:40	Navigating the Intersection of Breast Cancer and Bone Health: the Role of Denosumab in Preventing Skeletal-Related Events	Li-Kun Ko	Chin-Yao Lin
14:40-15:00	Coffee Break		
From Translational Research to Clinical Practice: The Role of TIL Assessment in Clinical Action			
15:00-15:30	Potential Role of TIL Assessment in Clinical Practice?	Sherene Loi	Chen-Hsiang Chang
15:30-16:00	What Should We Do on Monday Morning?	TNBC	Yuan-Ching Chang
		ER+	Dwan-Ying Chang
		HER2+	Wei-Pang Chung
16:00-16:20	Award Ceremony /Closing		Shou-Tung Chen

2024 Taipei International Breast Cancer Symposium

TBCS-GBCC Joint Session: When EAST meets WEST

Room 701B, Taipei Nangang Exhibition Center, Hall 2

Sat., October 26, 2024

Time	Topic	Speaker	Moderator
10:30-10:50	Screening, Diagnosis and Surveillance Between East and West	Eun Sook Ko	Ming-Yang Wang Hee Jeong Kim
10:50-11:10	Difference in Surgical Considerations and Oncoplastic Surgery Between East and West	Wen-Ling Kuo	
11:10-11:30	Difference in Medical Considerations and Survivorship Between East and West	Hyun Jo Youn	
11:30-12:00	Panel Discussion What Are the Unique Surgical Needs in Asian Population and How to Meet Them?	Eun Sook Ko Wen-Ling Kuo Hyun Jo Youn Yoo-Soek Kim Chih-Chiang Hung	
12:00-12:40	Lunch		
12:40-13:00	Break		

2024 Taipei International Breast Cancer Symposium

Young Doctors Forum & Young Doctors Debate

Room 701B, Taipei Nangang Exhibition Center, Hall 2

Sat., October 26, 2024

Young Doctors Forum (YDF)

13:00-13:05	Opening	Chi-Cheng Huang	
13:05-13:30	How to Ask Translational Questions?	Shiuan Chen	
13:30-13:55	Agonies of Young Doctors within the South Korean Health Care System	Junwon Min	
13:55-14:00	Q&A	ALL	
14:00-14:05	Break		

Young Doctors Debate (YDD)

14:05-14:45	Should ALND be Performed in ypN1micro Luminal Breast Cancer patient with Initial cN1 After Neoadjuvant Chemotherapy?	YDF Invitees	Wen-Ling Kuo
14:45-15:25	Should Adjuvant Pembrolizumab be Considered in Early TNBC Patients Achieving pCR After Neoadjuvant Chemotherapy Combined with Immunotherapy?		Chun-Yu Liu
15:25-15:30	QA & Closing	Jeong Eon Lee	
	Group Photo	ALL	

2024 Taipei International Breast Cancer Symposium

Oral Presentation

Room 702, Taipei Nangang Exhibition Center, Hall 2

Sat., October 26, 2024

Time	#	Topic	Presenter
10:50-11:00	1	Collagen family proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics: a preliminary study with bioinformatics analysis	Chi-Cheng Huang
11:00-11:10	2	Integrative Omics Analysis Reveals DTX1 as a Key Marker and Drug Target in Breast Cancer	Yen-Dun Tzeng
11:10-11:20	3	Therapeutic Co-Targeting of the BTK/HER2 Axis Induces Iron Accumulation to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer	Chih-Ming Su
11:20-11:30	4	ATP synthasome contributes to efficient energy flux in malignant breast cancer	Chia-Jung Li
11:30-11:40	5	The application of a PI3K inhibitor and an AKT inhibitor in HER2-positive breast cancer cells with resistance to HER2-directed antibody-drug conjugates	Wei-Pang Chung
11:40-11:50	6	Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression	Joseph Lin
11:50-12:00	7	SLC6A14-Mediated Glutamine Metabolism Reprogramming Enhances Cancer Stemness for Early Onset of Breast Cancer	Meng-Xia Su
12:00-12:10	8	Discovery and Biological Evaluation of a Novel Inhibitor for Human Breast Cancer Treatment	Cheng-Chiao Huang
12:10-12:20	9	Enhancing the Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using Artificial Intelligence	Jijung Jung
12:20-12:30	10	Pattern of failure and timing of progression on CDK4/6 inhibitor as first line therapy for HR+HER2- metastatic breast cancer invading different organ	Ruoh-Yun Gau
12:30-13:30		Lunch & Coffee Break	
13:10-13:20	11	Prognostic effects of ABCB1 and TMEM14B expression in triple-negative breast cancer	Sin-Hua Moi
13:20-13:30	12	Co-targeting PD-L1 and CDK4 benefits plasticizer-associated early-onset breast cancer	Shu-Wei Hu
13:30-13:40	13	Mechanistic Insights into Melittin's Efficacy Against Tamoxifen-Resistant Breast Cancer: Apoptosis, Proliferation, and Migration Modulation	Min-Hua Wu
13:40-13:50	14	LOC100506691, a long noncoding RNA, acts as novel oncogene in regulating breast cancer growth	Kian Hwee Chong
13:50-14:00	15	Molecular characterization of HER2 low breast cancers reveals a biologically and clinically distinct entity with heterozygous loss of ERBB2	Xintao Qiu
14:00-14:10	16	Using Bilateral Thoracoabdominal Flaps for Extensive Defects After Bilateral Mastectomy for Inflammatory Breast Cancer	Ryohei Katsuragi
14:10-14:20	17	Case Report of Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer Patient	Masahiro Yoshida
14:20-14:30	18	exoLinc-p21s: a short lincRNA-p21-engineered exosome as a chemosensitizer for targeting DDB2-mediated DNA repair	Yu-Hao He
14:30-14:40	19	LXPB5268 combined with neoadjuvant chemotherapy in early-stage Triple-Negative Breast Cancer patients	Chin-Yin Kuo
14:40-15:00		Coffee Break	
15:00-15:10	20	Multi-omics and spatial transcriptomics unveil the role of ferroptosis suppressor FANCD2 in clinicopathology and predicting immunotherapy response in breast cancer	Hung-Yu Lin
15:10-15:20	21	Combination of endocrine therapy, gonadotropin-releasing hormone agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2-metastatic breast cancer patients: final updates from PEER study	I-Chun Chen
15:20-15:30	22	Circulating CD3+CD8+ T lymphocytes as indicators of disease status in patients with early breast cancer	Hui-Ping Hsu